Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Accumulated Expenses (2016 - 2021)

Assembly Biosciences has reported Accumulated Expenses over the past 7 years, most recently at $3.7 million for Q3 2021.

  • Quarterly results put Accumulated Expenses at $3.7 million for Q3 2021, down 15.88% from a year ago — trailing twelve months through Sep 2021 was $3.7 million (down 15.88% YoY), and the annual figure for FY2020 was $4.4 million, down 7.92%.
  • Accumulated Expenses for Q3 2021 was $3.7 million at Assembly Biosciences, up from $3.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ASMB hit a ceiling of $10.1 million in Q1 2019 and a floor of $3.7 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $4.6 million (2020), compared with a mean of $5.5 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 222.84% in 2017 and later tumbled 54.31% in 2020.
  • Assembly Biosciences' Accumulated Expenses stood at $6.4 million in 2017, then fell by 26.84% to $4.6 million in 2018, then rose by 3.84% to $4.8 million in 2019, then fell by 7.92% to $4.4 million in 2020, then decreased by 15.75% to $3.7 million in 2021.
  • The last three reported values for Accumulated Expenses were $3.7 million (Q3 2021), $3.7 million (Q2 2021), and $4.3 million (Q1 2021) per Business Quant data.